Literature DB >> 8407891

The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase.

N Navaratnam1, J R Morrison, S Bhattacharya, D Patel, T Funahashi, F Giannoni, B B Teng, N O Davidson, J Scott.   

Abstract

The messenger RNA for apolipoprotein B undergoes a discrete and specific C to U editing of nucleotide 6666. This generates a stop translation codon and defines the carboxyl terminus of apolipoprotein B48. A 27-kDa rat intestinal protein that does not itself edit apolipoprotein B mRNA, but confers editing activity on chick intestinal extracts that do not have intrinsic editing activity, has recently been identified and its cDNA cloned (Teng, B., Burant, C. F., and Davidson, N. O. (1993) Science 260, 1816-1819). Here we show that p27 is homologous in the zinc coordinating region of the active site to cytidine deaminases from Escherichia coli, Bacillus subtilis, yeast, and man and to deoxycytidylate deaminases from T2 and T4 bacteriophages and man. p27 expressed in Xenopus laevis oocyte extracts has cytidine deaminase activity and specifically confers editing activity on chick intestinal extracts. The homologous E. coli cytidine deaminase does not confer editing activity. The zinc-specific chelating agent o-phenanthroline abolishes p27 activity and site-specific apolipoprotein B mRNA editing in rat enterocyte editing extracts. We conclude that p27 is the catalytic subunit of the apolipoprotein B mRNA editing enzyme and is a zinc-containing cytidine deaminase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407891

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  Involvement of a site-specific trans-acting factor and a common RNA-binding protein in the editing of chloroplast mRNAs: development of a chloroplast in vitro RNA editing system.

Authors:  T Hirose; M Sugiura
Journal:  EMBO J       Date:  2001-03-01       Impact factor: 11.598

Review 2.  APOBEC family proteins: novel antiviral innate immunity.

Authors:  Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 3.  An overview of cytidine deaminases.

Authors:  Naveenan Navaratnam; Rizwan Sarwar
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 4.  Evaluation of molecular models for the affinity maturation of antibodies: roles of cytosine deamination by AID and DNA repair.

Authors:  Mala Samaranayake; Janusz M Bujnicki; Michael Carpenter; Ashok S Bhagwat
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

Review 5.  Nuclear reprogramming and its role in vascular smooth muscle cells.

Authors:  Silvio Zaina; Maria del Pilar Valencia-Morales; Fabiola E Tristán-Flores; Gertrud Lund
Journal:  Curr Atheroscler Rep       Date:  2013-09       Impact factor: 5.113

Review 6.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

Review 7.  CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes.

Authors:  A Bhushan; L R Covey
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

8.  Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA.

Authors:  William C Solomon; Wazo Myint; Shurong Hou; Tapan Kanai; Rashmi Tripathi; Nese Kurt Yilmaz; Celia A Schiffer; Hiroshi Matsuo
Journal:  Nucleic Acids Res       Date:  2019-08-22       Impact factor: 16.971

9.  APOBEC3G targets specific virus species.

Authors:  Masayuki Kobayashi; Akifumi Takaori-Kondo; Keisuke Shindo; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Molecular cloning of a human small intestinal apolipoprotein B mRNA editing protein.

Authors:  C Hadjiagapiou; F Giannoni; T Funahashi; S F Skarosi; N O Davidson
Journal:  Nucleic Acids Res       Date:  1994-05-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.